# A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy

> **NCT02994147** · PHASE2 · COMPLETED · sponsor: **TWi Biotechnology, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Hemophilic Arthropathy

## Interventions

- **DRUG:** Placebo
- **DRUG:** AC-201CR

## Key facts

- **NCT ID:** NCT02994147
- **Lead sponsor:** TWi Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-21
- **Primary completion:** 2019-04-18
- **Final completion:** 2019-10-02
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02994147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02994147, "A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02994147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*